8-K: Assertio Holdings Delays Tender Offer Launch to May 14

Assertio Holdings and Garda Therapeutics have mutually agreed to postpone the tender offer for Assertio's shares and convertible notes to May 14, 2026.

Summary

• Assertio Holdings, Inc. announced on May 8, 2026, that it has mutually agreed with Garda Therapeutics, Inc. to delay the launch of the tender offer to acquire all outstanding shares of Assertio.
• The tender offer, initially planned under an amended and restated merger agreement dated May 1, 2026, will now commence on May 14, 2026.
• The acquisition price remains $21.80 per share in cash, totaling $153.2 million.
• Assertio also plans to delay the launch of the tender offer for its outstanding Convertible Senior Notes until May 14, 2026.
• The company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral development. While a delay can introduce uncertainty, the mutual agreement and clear new timeline suggest the deal is progressing, albeit with a slight procedural adjustment.

Negatives

• The launch of the tender offer to acquire Assertio's shares has been delayed.
• The launch of the tender offer for Assertio's Convertible Senior Notes has also been delayed.

Risks

• Risks associated with the timing of the closing of the proposed transaction, including the possibility that a condition to closing would not be satisfied within the expected timeframe or at all.
• Uncertainties regarding the number of Assertio's stockholders who will tender their shares in the offer.
• The possibility of competing offers being made.
• The potential for a governmental entity to prohibit, delay, or refuse to grant approval for the consummation of the transaction.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the transaction.
• The outcome of any legal proceedings that may be instituted against the parties and others related to the transaction.
• Unanticipated difficulties or expenditures relating to the proposed transaction.
• The effect of the announcement or pendency of the proposed transaction on Assertio's business and operating results, including the response of business partners and competitors and potential difficulties in employee retention.

Future Outlook

The tender offer to acquire all outstanding shares of Assertio and its Convertible Senior Notes is now scheduled to commence on May 14, 2026. Assertio expects to file its Schedule 14D-9 on the same date.

Management Comments

• Assertio announced that it has reached a mutual agreement with Garda Therapeutics to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026.
• Assertio will also delay the launch of the previously announced tender offer for all outstanding Convertible Senior Notes until May 14, 2026.

Industry Context

StockSavvy.ai notes that delays in tender offer launches are not uncommon in M&A transactions, often due to the need for further regulatory review, due diligence, or negotiation of terms. This extension suggests that parties are working through necessary steps to ensure a smooth closing.

Legal Proceedings

• Potential legal proceedings related to the transaction are mentioned as a risk factor.

Stakeholder Impact

• Shareholders: The delay may cause short-term uncertainty, but the core terms of the acquisition remain the same. They are advised to read the tender offer materials carefully.
• Creditors: The acquisition by Garda Therapeutics is expected to proceed, which may impact existing debt structures.
• Employees: Potential difficulties in employee retention are noted as a risk due to the pendency of the transaction.

Next Steps

• Garda Therapeutics and Audi Merger Sub, Inc. will file a Schedule TO, including an offer to purchase, letter of transmittal, and other related materials with the SEC.
• Assertio Holdings, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• The tender offer for Assertio's common stock will commence on May 14, 2026.
• The tender offer for Assertio's Convertible Senior Notes will commence on May 14, 2026.

Key Dates

Recommendation

The filing primarily concerns a procedural delay in a previously announced acquisition. While the deal terms remain intact, the delay itself introduces a minor element of uncertainty. Investors should await the commencement of the tender offer and the filing of the Schedule 14D-9 for more detailed information before making significant decisions. The current recommendation is to hold.

Keywords

Assertio Holdings, Garda Therapeutics, Tender Offer, Merger Agreement, Convertible Senior Notes, SEC Filing, Form 8-K, Acquisition